Stroke, Acute Hemiplegia, Apraxia Clinical Trial
— AOTOfficial title:
Study on the Effectiveness of Action Observation Treatment (AOT) as a Rehabilitation Tool in Acute Stroke Patients and in Chronic Stroke Patients With Apraxia: a Randomized Controlled Trial
Epidemiological studies report that 85% of stroke survivors show hemiparesis and a percentage ranging from 55% to 75% report upper limb functional impairment. Early rehabilitation in stroke patients with motor disorders can be effective to restore the affected function and to improve the performance of daily activities. Up to now, different methods and techniques have been used to recover motor functions in stroke patients. However, none of these has been conclusively proven to be more effective than the others. The clinical benefits induced by motor rehabilitation are closely related to "neuroplasticity". The main aim of the present study is to assess the efficacy of action observation treatment, based on Mirror Neuron System (MNS), in the rehabilitation of upper limb motor functions in acute stroke patients. The study will also aim at assessing neuroplasticity within areas belonging to the MNS through functional magnetic resonance (fMRI).
Status | Recruiting |
Enrollment | 80 |
Est. completion date | June 2015 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion Criteria: - first ever ischemic or hemorrhagic stroke confirmed by CT/MRI, no later than 30 days from acute event, or chronic stroke patients (more than three months from the acute event) with apraxia, - aged 18-85 years, - Upper limb plegia or paresis with muscle strength in grasping Medical Research Council (MRC) < 4, - ability to understand and carry out simple verbal instruction, - Mini Mental State Examination (MMSE) = 20. Exclusion Criteria: - previous cerebral ischemic or hemorrhagic event, - severe psychiatric disorders, - pre-existing rheumatic, orthopedic or muscular affection involving the upper limb, - moderate to severe fluent aphasia, - Neglect. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Health Services Research
Country | Name | City | State |
---|---|---|---|
Italy | Neuromed IRCCS, Istituto Neurologico Mediterraneo | Pozzilli | Isernia |
Lead Sponsor | Collaborator |
---|---|
Neuromed IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Fugl-Meyer Assessment of Motor Recovery after Stroke (FMA), (L Jääskö 1975) | FMA is a measuring system of upper limb motor disability indicated to monitor the degree of motor recovery after stroke during hospitalization. It looks like a questionnaire that describes the reflexes, the synergies of movement, coordination and speed of movement. Each task can receive a score ranging from 0 (no movement) and 2 (normal movement). The cumulative score and the profile of the scores indicate the degree of activity remaining motor and the need of rehabilitation. | at baseline (T1) | Yes |
Primary | Functional Independence Measure (FIM), (Hamilton, 1987) | FIM is a system of measurement of disability indicated to monitor patients during hospitalization. It looks like a questionnaire describing 18 activities of daily living (13-sphincteric motor, cognitive 5). Each task can receive a score ranging from 1 (complete dependence on others) and 7 (complete self-sufficiency). The cumulative score and the profile of the scores in the different items indicate the level of dependence even in the elementary activities of daily living, and above all the need for assistance. | at baseline (T1) | Yes |
Primary | FMA | at end-treatment, that is 15 days after starting treatment (T2) | Yes | |
Primary | FIM | at end-treatment, that is 15 days after starting treatment (T2) | Yes | |
Primary | FMA | 2 months after starting treatment (T3) | Yes | |
Primary | FIM | 2 months after starting treatment (T3) | Yes | |
Primary | FMA | 6 months after starting treatment (T4) | Yes | |
Primary | FIM | 6 months after starting treatment (T4) | Yes | |
Secondary | Functional Magnetic Resonance (fMRI) | Magnetic resonance (MR) images will be recorded on a 3.0 Tesla "GE Signa HDxt 3T" using standard echo planar imaging and a standard radio frequency, head coil phased array for signal received. 39 axial slice positions (slice thickness, 3 mm; no interslice gap) orientated in the anterior±posterior commissure plane covering the brain volume above the fronto-temporo-parietal areas will be acquired. The following sequences will be used: gradient echo planar imaging, sequence repetition time (TR), 3000 s; signal (echo)-gathering time (TE), 20 ms; FOV, 288x288 mm (FOV, field of view); matrix size, 96x96; in-plane resolution, 3 x 3 x 3 mm. In addition, high-resolution anatomical images of the entire brain will be obtained using a FSPGR strongly T1-weighted sequences: TR, 7 ms; TE, 3 ms (flip angle, a =13°) ir prep = 450, FOV, 256 mm, matrix size, 256x256, 180 axial slices with 1 mm single slice thickness. | at baseline (T1) | Yes |
Secondary | fMRI | at end-treatment, that is 15 days after starting treatment (T2) | Yes |